Experimental drug BL-M02D1 takes on tough lung cancers

NCT ID NCT05949619

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests an experimental drug called BL-M02D1 in 14 people with advanced non-small cell lung cancer that has not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. It is too soon to know if it will work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M02D1 (an experimental drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for advanced lung cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early, small trial (14 people) focused on safety and dosing. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.